The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Abstract
OBJECTIVE: To determine whether use of glucagon-like peptide 1 (GLP-1) receptor agonists (RA) is associated with increased risk of thyroid cancer. RESEARCH DESIGN AND METHODS: A nested case-control analysis was performed with use of the French national health care insurance system (SNDS) database. Individuals with type 2 diabetes treated with second-line antidiabetes drugs between 2006 and 2018 were included in the cohort. All thyroid cancers were identified through hospital discharge diagnoses and medical procedures between 2014 and 2018. Exposure to GLP-1 RA was measured within the 6 years preceding a 6-month lag-time period and considered as current use and cumulative duration of use based on defined daily dose (≤1, 1 to 3, >3 years). Case subjects were matched with up to 20 control subjects on age, sex, and length of diabetes with the risk-set sampling procedure. Risk of thyroid cancer related to use of GLP-1 RA was estimated with a conditional logistic regression with adjustment for goiter, hypothyroidism, hyperthyroidism, other antidiabetes drugs, and social deprivation index. RESULTS: A total of 2,562 case subjects with thyroid cancers were included in the study and matched with 45,184 control subjects. Use of GLP-1 RA for 1-3 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio [HR] 1.58, 95% CI 1.27-1.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.04-3.05). CONCLUSIONS: In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1-3 years of treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Concerns regarding the validity of outcomes have emerged, particularly owing to the reliance on indirect indicators such as the calcitonin test, carcinoembryonic antigen measurement, or vandetanib treatment to distinguish between MTC and non-MTC. This approach introduces the potential for misclassification.21,25”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“GLP-1 RA use for 1–3 years was associated with increased risk for any thyroid cancer (adjusted HR = 1.58 [CI 1.27–1.95]) and MTC (adjusted HR = 1.78 [CI 1.04–3.05]).25”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“In addition, five studies included analyses considering different lag times for outcome assessment, while two studies provided distinct information differentiating between thyroid cancer in general and MTC.25,38,51–53”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“GLP-1 RA use for 1–3 years was associated with increased risk for any thyroid cancer (adjusted HR = 1.58 [CI 1.27–1.95]) and MTC (adjusted HR = 1.78 [CI 1.04–3.05]).25”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Of note, there was a large variation in the percentage of cases reported as MTC between the two studies that included this distinction.25,38”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Two studies reported statistically significant findings of increased risk for thyroid cancer in those exposed to GLP-1 RA.25,38”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Of all thyroid cancer cases identified, 15% were MTC, which is higher than expected and might be related to methods used for defining MTC (e.g., testing for calcitonin test/carcinoembryonic antigen or vandetanib treatment).25”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Similarly, the potential for residual confounding (e.g., limited evaluation of specific risk factors for thyroid cancer such as obesity, neck radiation, and family history of thyroid cancer) and the role of surveillance bias (e.g., clinicians might be more likely to do a thyroid exam or ultrasound on patients taking GLP-1 RA) are important considerations that have been not thoroughly assessed.25,”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Consistent with previous studies, they also found a signal of disproportionate reporting of GLP-1 RA and overall thyroid cancer and MTC, including 606 reports (mostly from exenatide and liraglutide).25”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Recent investigations have highlighted the association between various neoplasms, such as thyroid, breast, and cholangiocarcinoma, and GLP-1 RAs [105-107].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [107]
In the citing paper
“the use of GLP-1 RAs for a duration of 1–3 years was associated with a heightened risk of all thyroid cancers, presenting an adjusted hazard ratio of 1.58 (95% CI 1.27–1.95) and an adjusted HR of 1.78 (95% CI 1.04–3.05), specifically for medullary thyroid cancer.”
In the citing paper
“A case-control study of health insurance data from France indicated an increased risk for thyroid carcinoma with GLP-1RA treatment, with an HR of 1.58 (95% CI 1.27–1.95) (78).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [78]
In the citing paper
“Recent health insurance data from France are indicative of an elevated risk of medullary thyroid carcinoma in individuals treated with GLP-1RAs versus other glucose-lowering agents (35 cases, hazard ratio [HR] 1.78 [95% CI 1.04–3.05]) (78).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [78]
In the citing paper
“in epidemiological studies a significant association with GLP-1RA treatment could be detected for medullary, but not for papillary cancer.12”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [12]
In the citing paper
“A similar problem affects observational studies; the main survey attempting to discriminate MTC from PTC 12 used indirect markers of limited reliability.21,22”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [12]
In the citing paper
“which was also confirmed by analyses of serious adverse events reported to the US Food and Drug Administration (FDA) 11,13 and the World Health Organization's pharmacovigilance database Vigi-Base.12,14”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [12]
In the citing paper
“Some retrospective observational studies detected an increased risk of thyroid cancer in association with GLP-1RA treatment, 11,12”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [12]
In the citing paper
“This meta-analysis suggests that GLP-1RA treatment may be associated with a moderate increase in risk of thyroid cancer, not dissimilar in its extent from that reported by a recent observational study, 12”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [12]
In the citing paper
“Also, the use of DPP4-i was found to be associated with a higher risk of thyroid cancer, leading the authors to hypothesize that this association might be partly explained by increased endogenous GLP-1 levels after the inhibition of DPP-4 [132].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [132]
In the citing paper
“The results showed that using GLP-1 RAs increased the risk of both medullary thyroid cancer and thyroid cancer overall, in particular after 1–3 years of treatment exposure (especially for male subjects) [132].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [132]
In the citing paper
“Also, the use of DPP4-i was found to be associated with a higher risk of thyroid cancer, leading the authors to hypothesize that this association might be partly explained by increased endogenous GLP-1 levels after the inhibition of DPP-4 [132].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [132]
Citations
Cites
van Puijenbroek, E., Bate, A., Leufkens, H. G. M., Lindquist, M., Orre, R., & Egberts, T. C. G. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.668 · Cited by 1,385
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Bezin, J., Duong, M., Lassalle, R., Droz‐Perroteau, C., Pariente, A., Blin, P., & Moore, N. D. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4233 · Cited by 586
Self-citationBiological actions and therapeutic potential of the glucagon-like peptides
Drucker, D. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.31068 · Cited by 509
Essebag, V., Platt, R. W., Abrahamowicz, M., & Pilote, L. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-5 · Cited by 234
Alves, C., Batel-Marques, F., & Macedo, A. F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.008 · Cited by 186
Asymptotic Theory for Nested Case-Control Sampling in the Cox Regression Model
Goldstein, L. J., & Langholz, B. M. (1992) · The Annals of Statistics · doi:10.1214/aos/1176348895 · Cited by 139
Nauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1825 · Cited by 94
Waser, B., Beetschen, K., Pellegata, N. S., & Reubi, J. C. (2011) · Neuroendocrinology · doi:10.1159/000330447 · Cited by 80
Flagged first, then by citations
Cited by
Sorted by citations
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Moiz, A., Filion, K. B., Toutounchi, H., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01590 · Cited by 149
Low-Grade Chronic Inflammation: a Shared Mechanism for Chronic Diseases
Cifuentes, M., Verdejo, H., Castro, P., Corvalán, A. H., Catterina Ferreccio, R., Quest, A. F. G., Kogan, M. J., & Lavandero, S. (2024) · Physiology · doi:10.1152/physiol.00021.2024 · Cited by 167
Glucagon‐like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study
Pasternak, B., Wintzell, V., Hviid, A., Eliasson, B., Gudbjörnsdottir, S., Jonasson, C., Hveem, K., Svanström, H., Melbye, M., & Ueda, P. (2024) · BMJ · doi:10.1136/bmj-2023-078225 · Cited by 125
Sibony, R. W., Segev, O., Dor, S., & Raz, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417147 · Cited by 151
Silverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
Schoretsanitis, G., Weiler, S., Barbui, C., Raschi, E., & Gastaldon, C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.23385 · Cited by 107
GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity
Dai, H., Li, Y., Lee, Y. A., Lu, Y., George, T. J., Donahoo, W. T., Lee, K. P., Nakshatri, H., Allen, J. M., Guo, Y. M., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.2681 · Cited by 112
Abushamat, L. A., Shah, P. A., Eckel, R. H., Harrison, S. A., & Barb, D. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.01.032 · Cited by 103
Semaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86
Zhou, J., Zheng, Y., Xu, B., Long, S., Zhu, L.-E., Liu, Y., Li, C., Zhang, Y., Liu, M., & Wu, X. (2024) · BMC Medicine · doi:10.1186/s12916-024-03274-6 · Cited by 88
Baxter, S. M., Lund, L. C., Andersen, J. H., Brix, T. H., Hegedüs, L., Hsieh, M. H.-C., Su, C. T.-T., Cheng, M. C.-Y., Chang, Z. C.-J., Lai, E. C.-C., et al. (2025) · Thyroid® · doi:10.1089/thy.2024.0387 · Cited by 81
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
Kim, J. A., & Yoo, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0242 · Cited by 71
Ayoub, M., Chela, H. K., Amin, N. A., Hunter, R., Anwar, J., Tahan, V., & Daglilar, E. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030944 · Cited by 78
GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16489 · Cited by 67
Bea, S., Son, H., Bae, J. H., Cho, S. W., Shin, J., & Cho, Y. M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15292 · Cited by 64
GLP-1RA Use and Thyroid Cancer Risk
Brito, J. P., Herrin, J. S., SWARNA, K. S., Ospina, N. S., Montori, V. M., Toro-Tobón, D., Umpierrez, G. E., Galindo, R. J., Deng, Y., Mickelson, M. M., et al. (2025) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2024.4852 · Cited by 70
Levy, S. M., Attia, A. S., Elshazli, R. M., Abdelmaksoud, A., Tatum, D. M., Aiash, H., & Toraih, E. A. (2024) · Cancers · doi:10.3390/cancers17010078 · Cited by 67
Feier, C., Vonica, R., Faur, A., Streinu, D., & Muntean, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084346 · Cited by 60
“[52] on the risk of thyroid cancer associated with GLP-1 receptor agonists diverges from our findings regarding semaglutide, suggesting a potential increased risk for thyroid cancer.”
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10192-9 · Cited by 56
Gilden, A. H., Catenacci, V. A., & Taormina, J. M. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202405210 · Cited by 58
Pediatric Obesity: Complications and Current Day Management
Vajravelu, M. E., Tas, E., & Arslanian, S. A. (2023) · Life · doi:10.3390/life13071591 · Cited by 64
Lin, A., Ding, Y., Li, Z., Jiang, A., Liu, Z., Wong, H. Z. H., Cheng, Q., Zhang, J., & Luo, P. (2025) · Biomarker Research · doi:10.1186/s40364-025-00765-3 · Cited by 60
Janež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzı́k, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 56
Putting GLP-1 RAs and Thyroid Cancer in Context: Additional Evidence and Remaining Doubts
Thompson, C. A., & Stürmer, T. (2023) · Diabetes Care · doi:10.2337/dci22-0052 · Cited by 51
Caruso, I., Di Gioia, L., Di Molfetta, S., Caporusso, M., Cignarelli, A., Sorice, G. P., Laviola, L., & Giorgino, F. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02441-z · Cited by 49
Huang, Y., Liao, W., Huang, J., Lin, Y., Yang, S., Huang, C., Wang, C., & Su, P. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15869 · Cited by 44
Psaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 47
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“GLP-1RAs versus other glucose-lowering agents (35 cases, hazard ratio [HR] 1.78 [95% CI 1.04–3.05]) ( 78).”
InfluentialPractice Patterns and Perspectives of the Off-Label Use of GLP-1 Agonists for Cosmetic Weight Loss
Han, S. H., Ockerman, K., Furnas, H., Mars, P., Klenke, A., Ching, J., Momeni, A., & Sorice-Virk, S. (2024) · Aesthetic Surgery Journal · doi:10.1093/asj/sjad364 · Cited by 40
Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events
He, L., Li, Q., Yang, Y., Li, J., Luo, W., Huang, Y., & Zhong, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1416985 · Cited by 40
Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 44
Anti-Diabetic Therapies and Cancer: From Bench to Bedside
Kounatidis, D. C., Vallianou, N. G., Karampela, Ι., Rebelos, E., Kouveletsou, M., Dalopoulos, V., Koufopoulos, P., Diakoumopoulou, E., Tentolouris, N., & Dalamaga, Μ. (2024) · Biomolecules · doi:10.3390/biom14111479 · Cited by 47
Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
Lisco, G., Tullio, A. D., Disoteo, O., Piazzolla, G., Guastamacchia, E., Sabbà, C., Geronimo, V. D., Papini, E., & Triggiani, V. (2023) · Endocrine Connections · doi:10.1530/ec-23-0257 · Cited by 44
Repurposing metabolic regulators: antidiabetic drugs as anticancer agents
Dhas, Y., Biswas, N., Divyalakshmi, M. R., Jones, L., & Ashili, S. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00204-z · Cited by 45
Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
Espinosa De Ycaza, A. E., Brito, J. P., McCoy, R. G., Shao, H., & Singh Ospina, N. (2024) · Thyroid · doi:10.1089/thy.2023.0530 · Cited by 37
Ayoub, M., Faris, C., Juranovic, T., Chela, H. K., & Daglilar, E. S. (2024) · Cancers · doi:10.3390/cancers16091625 · Cited by 38
Capuccio, S., Scilletta, S., Rocca, F. L., Miano, N., Marco, M. D., Bosco, G., Barbagallo, F. D. G., Scicali, R., Piro, S., & Pino, A. D. (2024) · Biomolecules · doi:10.3390/biom14060687 · Cited by 41
Valencia-Rincón, E., Rai, R., Chandra, V., & Wellberg, E. A. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194743 · Cited by 38
Nassar, M., Nassar, O., Abosheaishaa, H. M., & Misra, A. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02466-4 · Cited by 34
Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists
Kelly, C. A., & Sipos, J. A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae722 · Cited by 30
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 36
Grigoriadis, G., Koufakis, T., & Kotsa, K. (2023) · Medicina · doi:10.3390/medicina59112013 · Cited by 33
Chiang, C., Song, J., Chi, K., Chang, Y.-C., Xanthavanij, N., Chang, Y., Hsia, Y. P., Chiang, C.-H., Ghamari, A., Reynolds, K. L., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115170 · Cited by 31
Kamrul-Hasan, A. B. M., Alam, M. S., Dutta, D., Sasikanth, T., Aalpona, F. T. Z., & Nagendra, L. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2164 · Cited by 27
Alhajahjeh, A. A., Al‐Faouri, R., Bahmad, H. F., Bader, T., Dobbs, R. W., Abdulelah, A., Abou-Kheir, W. G., Davicioni, E., Lee, D. I., & Shahait, M. (2024) · Cancers · doi:10.3390/cancers16081538 · Cited by 31
GLP-1 Receptor Agonists and Suicidality—Caution Is Needed
Salvo, F., & Faillie, J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.23335 · Cited by 26
Self-citationTobaiqy, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00629-x · Cited by 25
Secondary diabetes mellitus in pheochromocytomas and paragangliomas
Moustaki, M., Paschou, S. Α., Vakali, E., Xekouki, P., Ntali, G., Kassi, E., Peppa, Μ., Ψαλτοπούλου, Θ., Tzanela, M., & Vryonidou, A. (2023) · Endocrine · doi:10.1007/s12020-023-03492-7 · Cited by 25
Zhou, J., Huang, W., Xie, Y., Shen, H., Liu, M., & Wu, X. (2024) · Endocrine · doi:10.1007/s12020-024-04112-8 · Cited by 30
Wang, L., Zhang, L., Ma, R., Zhang, Y., Chang, Q., & Yin, D. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf053 · Cited by 26
Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study
Morales, D. R., Bu, F., Viernes, B., DuVall, S. L., Matheny, M. E., Simon, K., Falconer, T., Richter, L. R., Ostropolets, A., Lau, W. C. Y., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0154 · Cited by 26
Thyroid cancer and insulin resistance
Brenta, G., & Fermo, F. D. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09849-7 · Cited by 22
Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists
Trevella, P., Ekinci, E. I., & MacIsaac, R. J. (2024) · Nephrology · doi:10.1111/nep.14336 · Cited by 22
Popovic, D. S., Patoulias, D., POPOVIC, L. S., Karakasis, P., Παπάνας, Ν., & Mantzoros, C. S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111758 · Cited by 22
GLP-1 receptor agonists in the context of cancer: the road ahead
Miousse, I. R. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00245.2025 · Cited by 20
Olszanecka‐Glinianowicz, M., Mazur, A., Chudek, J. T., Kos‐Kudła, B., Markuszewski, L., Dudek, D., Major, P., Małczak, P., Tarnowski, W., Jaworski, P., et al. (2023) · Nutrients · doi:10.3390/nu15071641 · Cited by 22
The feasibility and outcomes of metabolic and bariatric surgery prior to neoplastic therapy
Parmar, C. D., Mosleh, K. A., Aeschbacher, P., Halfdanarson, T. R., McKenzie, T. J., Rosenthal, R. J., Ghanem, O. M., Heneghan, H., Brennan, D. J., Wilkinson, M., et al. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.02.008 · Cited by 21
Quagliariello, V., Canale, M. L., Bisceglia, I., Iovine, M., Giordano, V., Giacobbe, I., Scherillo, M., Gabrielli, D., Maurea, C., Barbato, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011299 · Cited by 21
Daou, C. A. Z., Hosn, O. A., Ghzayel, L., & Mourad, M. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70038 · Cited by 19
Repurposing glucose-lowering drugs for cancer therapy
Luconi, M., Cantini, G., & Crescioli, C. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.04.010 · Cited by 19
Chen, H., Liu, S., Gao, S. H., Shi, H., Yan, Y., Xu, Y., Fang, J., Wang, W., Chen, H., & Liu, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-01206-9 · Cited by 25
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes
Sheth, K., Kim, S., Porterfield, L. R., Virani, S. S., Wadhwani, S., & Vaughan, E. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01319-6 · Cited by 20
Cedirian, S., Donati, M., Rapparini, L., Pampaloni, F., Plaça, M. L., Sgarzani, R., Negosanti, L., Raschi, E., & Starace, M. V. R. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01537-5 · Cited by 25
Egeberg, A., & Thyssen, J. P. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad039 · Cited by 19
Yan, Y., Gong, Y., Jiang, M., Gao, Y., Guo, S., Huo, J., Zhao, Z., & Li, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1170127 · Cited by 19
Kupnicka, P., Król, M., Żychowska, J., Łagowski, R., Prajwos, E., Surówka, A., & Chlubek, D. (2024) · Pharmaceuticals · doi:10.3390/ph17111470 · Cited by 22
Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial
Gamborg, M., Grand, M. K., Grell, K., Rosthøj, S., Pedersen‐Bjergaard, U., Torp-Pedersen, C. T., & Mørch, L. S. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101346 · Cited by 23
Tang, H., Zhang, B., Lu, Y., Donahoo, W. T., Ospina, N. S., Kotecha, P., Lu, Y., Tong, J., Smith, S. M., Rosenberg, E. I., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16147 · Cited by 18
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
Kałas, M., Stępniewska, E., Gniedziejko, M., Leszczyński-Czeczatka, J., & Siemiński, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093122 · Cited by 21
The Impact and Safety of GLP‐1 Agents and Breast Cancer
Parsons, K., Montalvo, M., Fischbach, N. A., Taylor, M. A., Alfaro, S., & Lustberg, M. B. (2025) · Cancer Medicine · doi:10.1002/cam4.70932 · Cited by 21
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 19
Mao, X., Zhang, X., Henry, L. L., Cheung, K. S., Yuen, M., Cheung, R. C., Seto, W., & Nguyen, M. H. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf163 · Cited by 19
Fahim, S. A., Attia, Y. M., Messiha, A. A., Nabawy, A. Y., Refaat, F., & El-Maadawy, W. H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118731 · Cited by 21
Khunti, K., Almalki, M., Chan, J. C. N., & Amod, A. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01458-6 · Cited by 17
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors
Lacroix, A., Bourdeau, I., Chasseloup, F., Kamenický, P., Lopez, A.-G., Louiset, E., & Lefèbvre, H. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00200-6 · Cited by 17
Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression
Marathe, S. J., Grey, E. W., Bohm, M. S., Joseph, S. C., Ramesh, A. V., Cottam, M. A., Idrees, K., Wellen, K. E., Hasty, A. H., Rathmell, J. C., et al. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00054-5 · Cited by 16
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 15
What is the evidence regarding the safety of new obesity pharmacotherapies
Vidal, J., Flores, L., Jiménez, A., Pané, A., & de Hollanda, A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01488-5 · Cited by 15
Integrating Artificial Intelligence with Mixed Reality to Optimize Health Care in the Metaverse
Roosan, D. (2024) · Springer series on cultural computing · doi:10.1007/978-3-031-57746-8_13 · Cited by 15
Riedinger, C. J., Sakach, J. C., Maples, J. M., Fulton, J., Chippior, J., OʼDonnell, B., O’Malley, D. M., & Chambers, L. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.07.008 · Cited by 17
Endogenous incretin levels and risk of first incident cancer: a prospective cohort study
Jujić, A., Godina, C., Belting, M., Melander, O., Holst, J. J., Ahlqvist, E., Gomez, M. F., Nilsson, P. M., Jernström, H., & Magnusson, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-27509-3 · Cited by 15
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Self-citationŁuniewski, M., Matyjaszek‐Matuszek, B., & Lenart-Lipińska, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134431 · Cited by 15
Exploring the potential impact of GLP-1 receptor agonists in cancer therapy
Aslam, B., Zafar, M. D. B., Changez, M. I. K., ABDULLAH, M., Safwan, M., QAMAR, B., SHINWARI, A., & Sanjana, R. A. I. (2023) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04101-5 · Cited by 14
Dharia, A., Desai, D., & Desai, K. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.02.005 · Cited by 14
Fawzy, M. S., Alenezy, A. K., Jishu, J. A., Khan, I., Dessouky, A., Abdelmaksoud, A., Limbach, K. E., & Toraih, E. A. (2025) · Cancers · doi:10.3390/cancers17091593 · Cited by 14
Lu, Y., Dai, H., Tang, H., Donahoo, W. T., George, T. J., Sun, R. C., Jiang, S., Tan, A. C., Guo, Y. M., Licht, J. D., et al. (2025) · Obesity · doi:10.1002/oby.24366 · Cited by 17
Ateiwi, Y. A., Mahmood, R. R., Wong, H. J., Low, C. E., Yau, C. E., Lee, A. R. Y. B., Eng, P. C., Lee, M., Chan, M. Y., & Sia, C. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113158 · Cited by 15
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown
Mannucci, E., & Dicembrini, I. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01135-0 · Cited by 14
le Roux, C. W., & Mondoh, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2311731 · Cited by 15
Li, J., Xie, J., Han, Y., Zhang, W., Wang, Y., & Jiang, Z. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0286 · Cited by 15
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 15
Lu, C., Xu, C., & Yang, J. (2024) · Medicina · doi:10.3390/medicina61010017 · Cited by 14
Incretin-Based Therapies and Cancer: What’s New?
Medenica, S., Bogdanović, J. M., Vekić, J., Vojinović, T., Babić, I., Bogdanovic, L. M., Maggio, V., El‐Tanani, M., & Rizzo, M. (2025) · Medicina · doi:10.3390/medicina61040678 · Cited by 13
Metadata
- Authors
- Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L.
- Affiliations
- Université de Bordeaux (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- 4Département de Pharmacologie Médicale et Toxicologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
- Inserm (FR)
- Corresponding author
- Faillie, Jean-Luc
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-11-10
- Volume
- 46
- Issue
- 2
- Pages
- 384-390
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4308701204
- Cited by
- 320
- References
- 17
- Citations by year
- 2026: 64 · 2025: 118 · 2024: 94 · 2023: 42 · 2022: 2
- FWCI
- 47.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
- Funders
- Agence Nationale de Sécurité du Médicament et des Produits de Santé (2019S015)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- GLP-1 receptor agonists, thyroid cancer, medullary thyroid carcinoma, type 2 diabetes, drug safety, cancer risk, treatment duration
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Thyroid Neoplasms, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
